Industry News

Mylan NV up to $100 million, but calculating the damage to the pharmaceutical company's reputation from its controversial price hikes may be more difficult. Mylan found itself at the center of a storm this week as a burst of outrage over a more than 500 percent increase in the price of EpiPen since 2007 forced the company to offer subsidies to cut out-of-pocket costs for some patients buying the life-saving allergy drug."/>
Mylan reputation at stake in EpiPen controversy [The Pittsburgh Tribune-Review]
Mylan NV up to $100 million, but calculating the damage to the pharmaceutical company's reputation from its controversial price hikes may be more difficult. Mylan found itself at the center of a storm this week as a burst of outrage over a more than 500 percent increase in the price of EpiPen since 2007 forced the company to offer subsidies to cut out-of-pocket costs for some patients buying the life-saving allergy drug."/>
Mylan profits, reputation at stake in EpiPen controversy [The Pittsburgh Tribune-Review]
Zosano Pharma Corporation concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com. No class has been certified in the above action."/>
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Zosano Pharma Corporation and Advises Investors With Losses in Excess of $10,000 Contact the Firm
American Renal Associates Holdings, Inc. concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com. No class has been certified in the above action."/>
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of American Renal Associates Holdings, Inc. and Advises Investors With Losses to Contact the Firm
Insys Therapeutics deceptively marketed and sold Subsys-- a spray form of the prescription opioid drug fentanyl-- to physicians treating patients for conditions such as neck and back pain. "This drug company's desire for increased..."/>
Drugmaker pushed opioid cancer drug on patients with neck pain: state lawsuit [Chicago Tribune]
Aurora Spine Corporation announces financial results for the three months and six months ended June 30, 2016.. "In Q2 2016 we generated our highest quarterly revenue since our inception and saw an increase in revenue over Q1, which had previously been our highest revenue quarter to date," said Trent Northcutt, President and CEO of Aurora Spine. ""/>
Aurora Spine Corporation Files Condensed Consolidated Financial Statements for the 3 Months and Six Months Ended June 30, 2016
Impax Laboratories, Inc. announced today that the Company had issued a voluntary nationwide retail level recall on August 19, 2016 for one lot of Lamotrigine Orally Disintegrating Tablet 200 mg. The Company is issuing this press release to provide further heightened awareness of this recall and to provide instructions to consumers, pharmacists, and wholesalers in possession of the affected product. Details related to the recalled..."/>
Impax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrigine Orally Disintegrating Tablet 200 mg Due to the Potential for 100 mg Blister Cards being Packaged in 200 mg Containers
Amarin Corporation plc, announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland, provided notice that the Issuer has exercised its option to mandatorily exchange all $118.734 million in aggregate principal amount of its 3.50% May 2014 Exchangeable Senior Notes due 2032 into American Depositary Shares of Amarin, with each ADS representing one..."/>
Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in May 2014 and November 2015
Flex Pharma, Inc. announced today that W. Larry Kenney, Ph.D., Professor of Physiology and Kinesiology at Penn State University, has joined the Company’ s Scientific Advisory Board."/>
Flex Pharma Announces Scientific Advisory Board Appointment and Management Change
Sophiris Bio Inc., a biopharmaceutical company developing topsalysin for the treatment of urological diseases, today announced that it has closed its previously announced underwritten public offering. The terms of the completed offering are consistent with the terms which were outlined in the Company's press release on August 23, 2016.. Piper Jaffray& Co. is acted as sole book-running manager for the..."/>
Sophiris Bio Closes Underwritten Public Offering
Transition Therapeutics Inc. has received shareholder approval for a plan of arrangement involving Transition, US-based healthcare company Opko Health, Inc., Opko Global Holdings, Inc. and the Transition shareholder, the company said. On 30 June, the companies announced a deal under which Opko Health would acquire Transition Therapeutics. Under the terms of the agreement approved by the boards of directors of..."/>
Transition Therapeutics Wins Shareholder Nod for USD 60m Opko Health Buyout
Accenture, Johnson& Johnson, and PepsiCo. Women in the U.S. earn, on average, 79 cents for every dollar a man earns, according to Census Bureau data, and the gap is more pronounced for African-American and Native American women and..."/>
A-B signs White House's equal pay pledge [St. Louis Post-Dispatch]
Emergent BioSolutions Inc.. On June 22, 2016, Emergent revealed that the U.S. government had issued two official solicitation notices specifying that it would only be purchasing 29.4 million doses of the BioThrax vaccine from Emergent,..."/>
Purcell Julie & Lefkowitz LLP Is Investigating Emergent BioSolutions Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary642 Articles
Information Technology587 Articles
Financials480 Articles
Health Care336 Articles
Industrials320 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.